



## Supplementary Materials

Figure S1




**Figure S1. Irinotecan upregulates HMOX-1 expression in mouse liver.** Mice in the IRT group were injected intraperitoneally with irinotecan hydrochloride, and mice in the NAC group were simultaneously injected intraperitoneally with NAC on the following day, alternately for 2 weeks, and the expression of HMOX-1 in the liver was determined by immunohistochemistry in the control group, IRT group and IRT+NAC group.

**Figure S2**




**Figure S2. Measurement of reactive oxygen species after treatment of L02 cells and primary mouse hepatocytes with different concentrations of irinotecan.** L02 cells ( $3 \times 10^5$ ) and PMH ( $3 \times 10^5$ ) were cultured in a 24-well plate and incubated with 6  $\mu$ M, 8  $\mu$ M and 10  $\mu$ M of irinotecan for 24 h, and then ROS levels were measured. **(A)** Determination of ROS activity in L02 cells and PMH after different concentrations of irinotecan treatment. **(B)** Quantitative analysis of fluorescence intensity of reactive oxygen species in L02 cells and PMH after treatment with different concentrations of irinotecan. Data are reported as mean  $\pm$  SD, and each graph is representative of at least 3 independent experiments. Comparison of values was performed by One-way ANOVA for unpaired data. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .

**Figure S3**




**Figure S3. Changes in intracellular ROS levels after different concentrations of NAC intervention with IRT treatment of hepatocytes.** (A) Primary mouse hepatocytes ( $3 \times 10^5$ ) were cultured in a 24-well plate and incubated with 10  $\mu$ M irinotecan and different concentration of NAC (0  $\mu$ M, 10  $\mu$ M, 100  $\mu$ M, 1000  $\mu$ M and 5000  $\mu$ M) for 24 h and the levels of intercellular ROS were measured. (B) L02 cells ( $3 \times 10^5$ ) were cultured in 24-well plates with 10  $\mu$ M irinotecan and different concentrations of NAC (0  $\mu$ M, 10  $\mu$ M, 100  $\mu$ M, 1000  $\mu$ M and 5000  $\mu$ M) for 24 h. Cell morphology and cell numbers were observed.

Figure S4



**Figure S4. Primary hepatocytes treated with IRT and NAC do not produce inflammatory factors.** We treated primary hepatocytes with irinotecan and NAC but there were no significant changes in the expression of Arg-1, IL-10, IL-6, IL-1 $\beta$ , and TNF- $\alpha$ . Data are reported as mean  $\pm$  SD, and each graph is representative of at least 3 independent experiments. Comparison of values was performed by One-way ANOVA for unpaired data. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

**Figure S5**



**Figure S5. Apoptosis assay under in vivo conditions.** Mice in the IRT group were injected intraperitoneally with irinotecan hydrochloride, and mice in the NAC group were simultaneously injected intraperitoneally with NAC on the following day, alternately for 2 weeks. Cleaved caspase 3 (A) level and TUNEL assay (B) were used to evaluate apoptosis in the liver.